The stock of Lantheus Holdings Inc (NASDAQ:LNTH) is a huge mover today! About 461,642 shares traded hands or 13.45% up from the average. Lantheus Holdings Inc (NASDAQ:LNTH) has risen 331.22% since March 29, 2016 and is uptrending. It has outperformed by 327.74% the S&P500.
The move comes after 7 months positive chart setup for the $299.74M company. It was reported on Oct, 31 by Barchart.com. We have $23.36 PT which if reached, will make NASDAQ:LNTH worth $509.56 million more.
Analysts await Lantheus Holdings Inc (NASDAQ:LNTH) to report earnings on November, 2. They expect $0.07 earnings per share, down 61.11% or $0.11 from last year’s $0.18 per share. LNTH’s profit will be $2.43 million for 30.89 P/E if the $0.07 EPS becomes a reality. After $0.24 actual earnings per share reported by Lantheus Holdings Inc for the previous quarter, Wall Street now forecasts -70.83% negative EPS growth.
Lantheus Holdings Inc (NASDAQ:LNTH) Ratings Coverage
Out of 5 analysts covering Lantheus Holdings (NASDAQ:LNTH), 2 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 40% are positive. Lantheus Holdings has been the topic of 9 analyst reports since August 31, 2015 according to StockzIntelligence Inc. The stock of Lantheus Holdings Inc (NASDAQ:LNTH) earned “Market Perform” rating by Wells Fargo on Wednesday, September 30. Jefferies maintained Lantheus Holdings Inc (NASDAQ:LNTH) on Monday, August 29 with “Buy” rating. The stock has “Outperform” rating given by RBC Capital Markets on Wednesday, February 24. On Monday, August 31 the stock rating was downgraded by Robert W. Baird to “Neutral”. On Friday, September 23 the stock rating was initiated by Credit Suisse with “Neutral”. The rating was downgraded by Credit Suisse to “Neutral” on Friday, December 11.
According to Zacks Investment Research, “Lantheus Holdings, Inc. is involved in developing, manufacturing, selling and distributing diagnostic medical imaging agents and products for diagnosis of cardiovascular and other diseases. It serves to hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, radiopharmacies and wholesalers. Lantheus Holdings, Inc. is based in NORTH BILLERICA, United States.”
More notable recent Lantheus Holdings Inc (NASDAQ:LNTH) news were published by: Fool.com which released: “Why Lantheus Holdings Inc. Sold Lower Friday” on September 09, 2016, also Marketwatch.com with their article: “Virtual Stock Exchange” published on July 30, 2014, Businesswire.com published: “Lantheus Holdings, Inc. Announces Public Offering of 5200000 Shares of Common …” on September 08, 2016. More interesting news about Lantheus Holdings Inc (NASDAQ:LNTH) were released by: Businesswire.com and their article: “Lantheus Holdings, Inc. Reports 2016 Second Quarter Financial Results” published on August 04, 2016 as well as Businesswire.com‘s news article titled: “Lantheus Holdings Announces Appointment of Jack Crowley as Interim Chief …” with publication date: December 10, 2015.
LNTH Company Profile
Lantheus Holdings, Inc., incorporated on November 30, 2007, develops, makes and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The Company’s portfolio of approximately 10 commercial products is spread across a range of imaging modalities. The Company’s contrast agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging or magnetic resonance imaging (MRI), which are used by physicians to progress the clarity of the diagnostic image. Radiopharmaceuticals are radioactive pharmaceuticals used by clinicians to perform nuclear imaging procedures. The Company’s imaging agents include contrast agents and medical radiopharmaceuticals (including technetium generators), including DEFINITY, TechneLite, Xenon Xe 133 Gas (Xenon), Cardiolite and Neurolite.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.